REG - Beximco Pharma. - Order re Extension to Publish Financial Results

Beximco PharmaceuticalsAnnouncement

28/01/2026 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260128:nRSb7767Qa&default-theme=true

RNS Number : 7767Q  Beximco Pharmaceuticals PLC  28 January 2026

28 January 2026

 

BEXIMCO PHARMACEUTICALS PLC.

 

Further Order re Request of Extension to Publish the Company's Financial
Results for 2025

 

Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.:
213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical
products and active pharmaceutical ingredients, announces further developments
with regards to the publication of its financial results for 2025.

 

The Company received correspondence on 13 January 2026 from the Bangladesh
Securities and Exchange Commission (BSEC) informing the Company that it is not
in a position to approve the Company's application for extensions to submit
and publish its Q3 2025 financial results, Annual Results to 30 June 2025, and
its first quarter financial results ended 30 September 2025. These requests
were previously made by the Company in April, October and November 2025. This
was followed by an Order from BSEC dated 15 January 2026, requiring the
Company to hold a meeting of the Board of Directors (including the BSEC's
proposed nine additional independent directors) within 12 days from the date
of the Order.

 

In response, the Company filed a Writ Petition in the High Court Division of
the Supreme Court of Bangladesh challenging the Order dated 15 January 2026.
At a hearing, the High Court Division issued a Rule requiring BSEC to show
cause as to why this Order should not be declared to have been made without
any lawful authority. The Court also directed that this matter should be heard
along with Writ Petition No. 525 of 2025 relating to the BSEC's proposed
appointment of an additional nine independent non-executive directors to the
Company's Board of Directors (BSEC Order). Further to the announcement on 19
December 2025, a High Court Bench has now been fixed for hearing of the Writ
Petition.

 

The Company will continue to make announcements regarding any developments
that need to be disclosed in accordance with its obligations under the AIM
Rules, whilst the temporary suspension is in place.

 

Shares continue to trade on the Dhaka Stock Exchange and the Chittagong Stock
Exchange.

 

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

 

 Beximco Pharma
 Mohammad Ali Nawaz, Chief Financial Officer

 Tel: +880 2 58611001, Ext. 20030

 Mohammad Asad Ullah, FCS

 Executive Director & Company Secretary

 Tel: +880 2 41060531, Ext. 10140

 SPARK Advisory Partners Limited (Nominated Adviser)

 Mark Brady / Andrew Emmott

 Tel: +44 (0)20 3368 3551 / 3555

 SP Angel Corporate Finance LLP (Broker)

 Matthew Johnson

 Tel: +44 (0) 20 3470 0470

 FTI Consulting

 Simon Conway / Sam Purewal

 Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 6000 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKFBPNBKDCDB



            Copyright 2019 Regulatory News Service, all rights reserved